| 规格: | 98% |
| 分子量: | 395.45 |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
Background:
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity[1].
Velagliflozin (1 mg/kg, p.o.) increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats[1].
[1]. Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273.
m.cnreagent.com